Levels of serum biomarkers from a two-year multicentre trial are associated with treatment response on knee osteoarthritis cartilage loss as assessed by magnetic resonance imaging: an exploratory study

Table 1 Patient characteristics

	Chondroitin sulfate (n = 57)	Celecoxib (n = 62)	P value
Male, n (%)	26 (46)	29 (47)	0.899*
Age, years	61 ± 8	61 ± 8	0.909
Body mass index, kg/m²	30.3 ± 6.42	32.5 ± 5.9	0.020
Synovial membrane thickness, mm	1.04 ± 0.23	1.01 ± 0.22	0.528
Bone marrow lesion, score	2.49 ± 3.20	2.63 ± 2.33	0.291
Synovial fluid volume, mL	14.8 ± 15.9	11.2 ± 12.3	0.210
Joint swelling and effusion, n (%)	37 (65)	32 (52)	0.142*
Pain VAS, mm	60.6 ± 15.9	57.2 ± 18.6	0.252
WOMAC
Total score (0–240)	121 ± 38	120 ± 46	0.934
Pain score (0–50)	24 ± 8	24 ± 9	0.909
Stiffness score (0–20)	11 ± 4	11 ± 4	0.694
Physical function score (0–170)	86 ± 29	85 ± 34	0.842
Quality of life (SF-36)
Physical component summary	36.31 ± 7.82	36.33 ± 8.13	0.610
Cartilage volume (mm³)
Medial
Compartment	4586 ± 1517	4324 ± 1309	0.445
Condyle	2881 ± 1020	2682 ± 833	0.448
Plateau	1705 ± 545	1642 ± 532	0.529

Data shown are number of patients (%) or mean ± SD. Continuous variables were compared using the Student's t test/Mann-Whitney test; p values in italics are statistically significant. *Proportions were compared using the chi-squared test/Fisher’s exact test. VAS visual analog scale, WOMAC Western Ontario and McMaster Universities Osteoarthritis Index, SF-36 Short Form 36

ISSN: 1478-6362